Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Cabozantinib||Preclinical||Actionable||In a preclinical study, Cometriq (cabozantinib) showed anti-tumor activity in human colorectal cancer explants (PMID: 25242168).||25242168|
|Unknown unknown||colorectal cancer||not applicable||Cabozantinib||Preclinical - Pdx||Actionable||In a preclinical study, Cometriq (Cabometyx, cabozantinib) treatment inhibited activation of PI3K/AKT/MTOR signaling pathway, reduced phosphorylation of Met, Ret, and Axl, and induced autophagy in colorectal cancer cells in culture, and decreased tumor vascularity, reduced tumor growth, and induced regression in patient-derived xenograft (PDX) models (PMID: 30026382).||30026382|
|PubMed Id||Reference Title||Details|
|(25242168)||Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.||Full reference...|
|(30026382)||Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.||Full reference...|